Informace o publikaci
miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities
| Autoři | |
|---|---|
| Rok publikování | 2009 |
| Druh | Článek v odborném periodiku |
| Časopis / Zdroj | Leukemia |
| Fakulta / Pracoviště MU | |
| Citace | |
| Doi | http://dx.doi.org/10.1038/leu.2008.377 |
| Obor | Onkologie a hematologie |
| Klíčová slova | CHRONIC LYMPHOCYTIC-LEUKEMIA; EXPRESSION; MICRORNAS |
| Popis | Chronic lymphocytic leukemia (CLL) is the most common leukemia in the western world and is characterized by a highly variable clinical course. CLL can be classified into two biological subtypes, according to the presence or absence of somatic mutations in the immunoglobulin heavy-chain variable region (IgVH). IgVH mutational status is of high-clinical relevance: cases with unmutated IgVH show a less favorable course with a rapid progression, whereas cases with mutated IgVH show a stable disease and longer survival. Unfavorable prognosis is also associated with the inactivation of an important tumor-suppressor p53; these patients harbor a deletion of 17p13 and this chromosomal abnormality is often accompanied by the mutation of the second TP53 allele, which leads to the complete elimination of p53 function. Moreover, a single mutation of one of the TP53 allele also occurs in a significant proportion of CLL cases. Patients with TP53 abnormalities typically do not respond to therapy and have a median survival of less than 3 years. |